 | • レポートコード：360iR22NB025 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、225ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医療 |
| Single User（1名利用、印刷可） | ￥732,452 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,472,452 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社の調査レポートでは、世界のドラッグデリバリー市場規模が2021年の13,435.7億ドルから、2022年に15,035.9億ドルに達すると予測しています。今後、2027年まで年平均12.08%で、26,643.5億ドルまでに成長する見込みです。本市場調査資料では、ドラッグデリバリーの世界市場を調査対象とし、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、ドラッグデリバリー別（注射ドラッグデリバリー、経鼻ドラッグデリバリー、接眼ドラッグデリバリー、肺性ドラッグデリバリー、局所ドラッグデリバリー）分析、デバイス種類別（高度ドラッグデリバリー、従来型ドラッグデリバリー）分析、流通チャネル別（病院薬局、小売薬局）分析、用途別（癌治療、心血管疾患治療、糖尿病治療、呼吸器疾患治療）分析、地域別（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）分析、競争状況、企業情報などを整理しました。本書では3M Company、AbbVie Inc.、Amgen Inc.、Antares Pharma, Inc.、AstraZeneca PLC、Bayer AG、Becton, Dickinson and Company、Boehringer Ingelheim Group、Bristol Myers Squibb、Eli Lilly and Company、Evonik Industries AG、F. Hoffmann-La Roche AG、Genmab A/Sなどの企業情報が含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界のドラッグデリバリー市場規模：ドラッグデリバリー別 - 注射ドラッグデリバリーの市場規模 - 経鼻ドラッグデリバリーの市場規模 - 接眼ドラッグデリバリーの市場規模 - 肺性ドラッグデリバリーの市場規模 - 局所ドラッグデリバリーの市場規模 ・世界のドラッグデリバリー市場規模：デバイス種類別 - 高度ドラッグデリバリーの市場規模 - 従来型ドラッグデリバリーの市場規模 ・世界のドラッグデリバリー市場規模：流通チャネル別 - 病院薬局チャネルの市場規模 - 小売薬局チャネルの市場規模 ・世界のドラッグデリバリー市場規模：用途別 - 癌治療における市場規模 - 心血管疾患治療における市場規模 - 糖尿病治療における市場規模 - 呼吸器疾患治療における市場規模 ・世界のドラッグデリバリー市場規模：地域別 - 南北アメリカのドラッグデリバリー市場規模 アメリカのドラッグデリバリー市場規模 カナダのドラッグデリバリー市場規模 ブラジルのドラッグデリバリー市場規模 ... - アジア太平洋のドラッグデリバリー市場規模 日本のドラッグデリバリー市場規模 中国のドラッグデリバリー市場規模 インドのドラッグデリバリー市場規模 韓国のドラッグデリバリー市場規模 台湾のドラッグデリバリー市場規模 ... - ヨーロッパ/中東/アフリカのドラッグデリバリー市場規模 イギリスのドラッグデリバリー市場規模 ドイツのドラッグデリバリー市場規模 フランスのドラッグデリバリー市場規模 ロシアのドラッグデリバリー市場規模 ... - その他地域のドラッグデリバリー市場規模 ・競争状況 ・企業情報 |
The Global Drug Delivery Market size was estimated at USD 1,343.57 billion in 2021 and expected to reach USD 1,503.59 billion in 2022, and is projected to grow at a CAGR 12.08% to reach USD 2,664.35 billion by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Drug Delivery to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Oral Drug Delivery, the market was studied across Injectable Drug Delivery, Nasal Drug Delivery, Ocular Drug Delivery, Pulmonary Drug Delivery, and Topical Drug Delivery.
Based on Device Type, the market was studied across Advanced and Conventional.
Based on Distribution Channels, the market was studied across Hospital Pharmacies and Retail Pharmacies.
Based on Application, the market was studied across Cancer, Cardiovascular Diseases, Diabetes, and Respiratory Diseases.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Drug Delivery market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Drug Delivery Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Drug Delivery Market, including 3M Company, AbbVie Inc., Amgen Inc., Antares Pharma, Inc., AstraZeneca PLC, Bayer AG, Becton, Dickinson and Company, Boehringer Ingelheim Group, Bristol Myers Squibb, Eli Lilly and Company, Evonik Industries AG, F. Hoffmann-La Roche AG, Genmab A/S, Gensco Pharma, GlaxoSmithKline PLC, IntelGenx Technologies Corporation, Johnson & Johnson Services, Inc., Medtronic PLC, MERCK KGaA, Nemera La Verpilliere SAS, Novartis AG, Pfizer Inc., Sanofi S.A., Teva Pharmaceutical Industries Ltd., and West Pharmaceutical Services, Inc..
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Drug Delivery Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Drug Delivery Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Drug Delivery Market?
4. What is the competitive strategic window for opportunities in the Global Drug Delivery Market?
5. What are the technology trends and regulatory frameworks in the Global Drug Delivery Market?
6. What is the market share of the leading vendors in the Global Drug Delivery Market?
7. What modes and strategic moves are considered suitable for entering the Global Drug Delivery Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Technological advancements
5.1.1.2. Increasing use of biological drugs
5.1.1.3. Swelling demand for effective drug delivery mechanisms
5.1.1.4. Significant increase in chronic diseases
5.1.2. Restraints
5.1.2.1. Increasing drug recalls and drug failures
5.1.2.2. Government regulations delaying the processes
5.1.2.3. Side effects and risk associated with the drugs
5.1.3. Opportunities
5.1.3.1. Rising demand for cost-effective healthcare treatment
5.1.3.2. Growing focus towards home care and self-administration
5.1.4. Challenges
5.1.4.1. Pricing pressure
5.1.4.2. Patents expiry
5.2. Cumulative Impact of COVID-19
6. Drug Delivery Market, by Oral Drug Delivery
6.1. Introduction
6.2. Injectable Drug Delivery
6.3. Nasal Drug Delivery
6.4. Ocular Drug Delivery
6.5. Pulmonary Drug Delivery
6.6. Topical Drug Delivery
7. Drug Delivery Market, by Device Type
7.1. Introduction
7.2. Advanced
7.3. Conventional
8. Drug Delivery Market, by Distribution Channels
8.1. Introduction
8.2. Hospital Pharmacies
8.3. Retail Pharmacies
9. Drug Delivery Market, by Application
9.1. Introduction
9.2. Cancer
9.3. Cardiovascular Diseases
9.4. Diabetes
9.5. Respiratory Diseases
10. Americas Drug Delivery Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Drug Delivery Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Drug Delivery Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.1.1. Quadrants
13.1.2. Business Strategy
13.1.3. Product Satisfaction
13.2. Market Ranking Analysis, By Key Player
13.3. Market Share Analysis, By Key Player
13.4. Competitive Scenario
13.4.1. Merger & Acquisition
13.4.2. Agreement, Collaboration, & Partnership
13.4.3. New Product Launch & Enhancement
13.4.4. Investment & Funding
13.4.5. Award, Recognition, & Expansion
14. Company Usability Profiles
14.1. 3M Company
14.1.1. Business Overview
14.1.2. Key Executives
14.1.3. Product & Services
14.2. AbbVie Inc.
14.2.1. Business Overview
14.2.2. Key Executives
14.2.3. Product & Services
14.3. Amgen Inc.
14.3.1. Business Overview
14.3.2. Key Executives
14.3.3. Product & Services
14.4. Antares Pharma, Inc.
14.4.1. Business Overview
14.4.2. Key Executives
14.4.3. Product & Services
14.5. AstraZeneca PLC
14.5.1. Business Overview
14.5.2. Key Executives
14.5.3. Product & Services
14.6. Bayer AG
14.6.1. Business Overview
14.6.2. Key Executives
14.6.3. Product & Services
14.7. Becton, Dickinson and Company
14.7.1. Business Overview
14.7.2. Key Executives
14.7.3. Product & Services
14.8. Boehringer Ingelheim Group
14.8.1. Business Overview
14.8.2. Key Executives
14.8.3. Product & Services
14.9. Bristol Myers Squibb
14.9.1. Business Overview
14.9.2. Key Executives
14.9.3. Product & Services
14.10. Eli Lilly and Company
14.10.1. Business Overview
14.10.2. Key Executives
14.10.3. Product & Services
14.11. Evonik Industries AG
14.11.1. Business Overview
14.11.2. Key Executives
14.11.3. Product & Services
14.12. F. Hoffmann-La Roche AG
14.12.1. Business Overview
14.12.2. Key Executives
14.12.3. Product & Services
14.13. Genmab A/S
14.13.1. Business Overview
14.13.2. Key Executives
14.13.3. Product & Services
14.14. Gensco Pharma
14.14.1. Business Overview
14.14.2. Key Executives
14.14.3. Product & Services
14.15. GlaxoSmithKline PLC
14.15.1. Business Overview
14.15.2. Key Executives
14.15.3. Product & Services
14.16. IntelGenx Technologies Corporation
14.16.1. Business Overview
14.16.2. Key Executives
14.16.3. Product & Services
14.17. Johnson & Johnson Services, Inc.
14.17.1. Business Overview
14.17.2. Key Executives
14.17.3. Product & Services
14.18. Medtronic PLC
14.18.1. Business Overview
14.18.2. Key Executives
14.18.3. Product & Services
14.19. MERCK KGaA
14.19.1. Business Overview
14.19.2. Key Executives
14.19.3. Product & Services
14.20. Nemera La Verpilliere SAS
14.20.1. Business Overview
14.20.2. Key Executives
14.20.3. Product & Services
14.21. Novartis AG
14.21.1. Business Overview
14.21.2. Key Executives
14.21.3. Product & Services
14.22. Pfizer Inc.
14.22.1. Business Overview
14.22.2. Key Executives
14.22.3. Product & Services
14.23. Sanofi S.A.
14.23.1. Business Overview
14.23.2. Key Executives
14.23.3. Product & Services
14.24. Teva Pharmaceutical Industries Ltd.
14.24.1. Business Overview
14.24.2. Key Executives
14.24.3. Product & Services
14.25. West Pharmaceutical Services, Inc.
14.25.1. Business Overview
14.25.2. Key Executives
14.25.3. Product & Services
15. Appendix
15.1. Discussion Guide
15.2. License & Pricing